ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia.
ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia.
复制标题
ALDH1 和足足蛋白表达模式可预测口腔白斑恶变的风险。
DOI：
10.3892/ol.2016.5379
复制
发表时间：
2017-01
期刊：
影响因子：
2.9
通讯作者：
Shindoh M
中科院分区：
文献类型：
--
作者：
Habiba U;Hida K;Kitamura T;Matsuda AY;Higashino F;Ito YM;Ohiro Y;Totsuka Y;Shindoh M
口腔白斑（OL）是一种临床诊断的口腔肿瘤前病变，口腔癌风险增加。然而，恶性转化的风险仍然难以评估。本研究的目的是检测醛脱氢酶1 （ALDH1）和podoplanin在OL中的表达模式，并确定它们在预测口腔癌发展中的作用。在本研究中，我们检测了79例OL患者的ALDH1和podoplanin的表达模式。在平均3.4年的随访期间，分析了蛋白表达与临床病理参数（包括口腔无癌生存期）之间的关系。ALDH1和podoplanin分别在61%和67%的患者中表达。Kaplan-Meier分析表明，这些蛋白的表达与口腔癌进展的风险相关。多因素分析显示，ALDH1和podoplanin的表达分别与恶性转化风险增加3.02倍和2.62倍相关。表达这两种蛋白的OL的恶性转化风险明显更高。点流行分析显示，66%的ALDH1和podoplanin共表达的患者发生口腔癌。综上所述，我们的数据表明，ALDH1和podoplanin在OL中的表达模式与口腔癌的发展有关，这表明ALDH1和podoplanin可能是识别口腔癌高风险OL患者的有用生物标志物。
Oral leukoplakia (OL) is a clinically diagnosed preneoplastic lesion of the oral cavity with an increased oral cancer risk. However, the risk of malignant transformation is still difficult to assess. The objective of the present study was to examine the expression patterns of aldehyde dehydrogenase 1 (ALDH1) and podoplanin in OL, and to determine their roles in predicting oral cancer development. In the present study, the expression patterns of ALDH1 and podoplanin were determined in samples from 79 patients with OL. The association between protein expression and clinicopathological parameters, including oral cancer-free survival, was analyzed during a mean follow-up period of 3.4 years. Expression of ALDH1 and podoplanin was observed in 61 and 67% patients, respectively. Kaplan-Meier analysis demonstrated that the expression of the proteins was correlated with the risk of progression to oral cancer. Multivariate analysis revealed that expression of ALDH1 and podoplanin was associated with 3.02- and 2.62-fold increased risk of malignant transformation, respectively. The malignant transformation risk of OL was considerably higher in cases with expression of both proteins. Point-prevalence analysis revealed that 66% of patients with co-expression of ALDH1 and podoplanin developed oral cancer. Taken together, our data indicate that ALDH1 and podoplanin expression patterns in OL are associated with oral cancer development, suggesting that ALDH1 and podoplanin may be useful biomarkers to identify OL patients with a substantially high oral cancer risk.